Mirati’s KRAS Inhibitor Gains Edge On Efficacy, But Safety Trails Amgen’s Competing Drug
Mirati’s adagrasib seems to have better efficacy data while Amgen’s sotorasib has the safety advantage, but oncologists aren’t issuing a verdict yet.
You may also be interested in...
Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.
Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.
Commercial EVP Murdo Gordon said launching sotorasib during the pandemic is a tougher challenge than encouraging doctors to screen lung cancer patients for KRAS G12C mutations and raising patient awareness.